BridgeBio Oncology names Pedro Beltran CEO in leadership reshuffle

BridgeBio Pharma
BridgeBio Oncology Therapeutics, Inc.

BridgeBio Pharma

BBIO

0.00

BridgeBio Oncology Therapeutics, Inc.

BBOT

0.00
  • BridgeBio Oncology Therapeutics named Pedro J. Beltran chief executive officer, effective April 20, 2026.
  • Beltran previously served as BBOT chief scientific officer, joining BridgeBio in 2020 as senior vice president of biology.
  • Idan Elmelech was appointed chief operating officer, effective April 20, 2026.
  • Elmelech previously served as senior vice president of strategy and business development, with remit spanning finance and accounting, corporate strategy, operations, business development.
  • Board appointed Neil Kumar executive chairman; former CEO Eli Wallace will move to senior adviser role.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604220900PRIMZONEFULLFEED9694736) on April 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.